Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type

Interventional

Phase

Not applicable

Age range

40 years - 80 years

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

60 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

1. Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
2. Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
3. Not having had PRP injection in the last year.
4. Knee pain ≥ 5 according to the visual pain scale.

Exclusion Criteria:

1. Those with significant neurological or cardiovascular disorders.
2. Those with active thrombovascular disease.
3. Those with joint or skin infections.
4. Those who have recently had an infectious disease.
5. Those infected with Hepatitis B, C, and HIV.
6. Those who have received intra-articular knee injections (hyaluronic acid, PRP, corticosteroids, and others) within the last year.
7. Those who use oral corticosteroids.
8. Those who have used NSAIDs within the last week.
9. Those who have used anti-platelet or anti-aggregant drugs within the last week.
10. Those with coagulation disorders.
11. Those with hemoglobin \<10 g/dl and platelet count \<100,000
12. Those with cancer.
13. Pregnant or breastfeeding women, drug addicts.
14. Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.
15. Those with diseases causing secondary osteoarthritis:

1. post-traumatic,
2. congenital or developmental diseases

1. Local diseases (leg length discrepancy, varus, valgus deformities, hypermobility syndromes, scoliosis)
2. Generalized diseases (Bone dysplasias, Metabolic disorders (hemochromatosis, ochronosis, Gaucher disease, hemoglobinopathy, Ehlers-Danlos disease))
3. Calcium storage diseases (calcium pyrophosphate storage disease, etc.)
4. Other bone and joint diseases (avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget's disease, osteoporosis, osteochondritis)
5. Other diseases

1. Endocrine diseases (Diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism)
2. Neuropathic arthropathy (Charcot joint)
3. Other (Frost, Kashin-Beck disease, Caisson disease) -

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Random assignment

Masking

Double masked

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Pamukkale University

Study start

Apr 1, 2026 Actual

Primary completion

Jan 18, 2027 Estimated

Study completion

Feb 27, 2027 Estimated

First posted

Mar 16, 2026 Actual

Last updated

Nov 9, 2026 Actual

Official study contacts

No central contact is listed. Check the locations and the official record.